Navigating The Unique Manufacturing Challenges In Cell And Gene Therapy And What We Can Learn From Our Past Experiences
- What are the unique challenges to the gene and cell therapy manufacturing processes?
- Why supply chain needs a lot of attention, from starting materials, vector banking, frozen vial to chain of custody and how to build it robustly
- How does cell and gene therapy capacity planning compare to products in the past?
- Re-thinking the capacity dilemma: CDMO, build our own facilities or partnership strategies for facility build, space sharing and co-control?
- Highlighting Sangamo’s approach to addressing these challenges